Ferroptosis meets inflammation: A new frontier in cancer therapy
Cancer Letters · 2025-06 · 620 · 217696
DOI: 10.1016/j.canlet.2025.217696 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025-06. Verfasst von Hu Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Surgery, Shanghai Mengchao Hospital, Shanghai University, Shanghai, 202800, China. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms, Inflammation. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 188 Literaturangaben.
Abstract (Originalsprache)
Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a critical player in cancer pathogenesis. Concurrently, inflammation, a key biological response to tissue injury or infection, significantly influences cancer development and progression. The interplay between ferroptosis and inflammation represents a promising yet underexplored area of research. This review synthesizes recent advances in understanding the molecular mechanisms governing their interaction, emphasizing how ferroptosis triggers inflammatory responses and how inflammatory mediators, such as TNF-α, regulate ferroptosis through iron metabolism and lipid peroxidation pathways. Key molecular targets within the ferroptosis-inflammation axis, including GPX4, ACSL4, and the NF-κB signaling pathway, offer therapeutic potential for cancer treatment. By modulating these targets, it may be possible to enhance ferroptosis and fine-tune inflammatory responses, thereby improving therapeutic outcomes. Additionally, this review explores the broader implications of targeting the ferroptosis-inflammation interplay in disease treatment, highlighting opportunities for developing innovative strategies to combat cancer. By bridging the gap in current knowledge, this review provides a comprehensive resource for researchers and clinicians, offering insights into the therapeutic potential of this intricate biological relationship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology Surgery, Shanghai Mengchao Hospital, Shanghai University, Shanghai, 202800, China.
- Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
- Boston Children's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
- Department of Oncology Surgery, Shanghai Mengchao Hospital, Shanghai University, Shanghai, 202800, China. Electronic address: ylx899@aliyun.com.
- Department of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China. Electronic address: zkjwcfzwh@163.com.
- Boston Children's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, Chin…
Zitieren
APA
Liu, H., Xue, H., Guo, Q., Xue, X., Yang, L., Zhao, K., & Liu, Y. (2025). Ferroptosis meets inflammation: A new frontier in cancer therapy. Cancer Letters, 620, 217696. https://doi.org/10.1016/j.canlet.2025.217696
Vancouver
Liu H, Xue H, Guo Q, Xue X, Yang L, Zhao K, et al. Ferroptosis meets inflammation: A new frontier in cancer therapy. Cancer Letters. 2025;620:217696. doi:10.1016/j.canlet.2025.217696
BibTeX
@article{Liu2025,
author = {Liu, Hu and Xue, Hui and Guo, Qian and Xue, Xutong and Yang, Lixue and Zhao, Kaijun and Liu, Yu'e},
title = {Ferroptosis meets inflammation: A new frontier in cancer therapy},
journal = {Cancer Letters},
year = {2025},
volume = {620},
pages = {217696},
doi = {10.1016/j.canlet.2025.217696}
}
EUVIMED